Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Humoral Immune Responses01:36

Humoral Immune Responses

87.9K
Overview
87.9K
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

2.7K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
2.7K
Antibody Actions01:26

Antibody Actions

4.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
4.1K
Cross-reactivity00:42

Cross-reactivity

34.0K
Overview
34.0K
Affinity and Avidity01:41

Affinity and Avidity

40.7K
Overview
40.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Meet the author: Constantinos Kurt Wibmer.

Structure (London, England : 1993)·2026
Same author

Influence of the broadly neutralizing antibody VRC01 on HIV breakthrough virus populations in antibody-mediated prevention trials.

Nature communications·2026
Same author

Defining the mechanism of cross-reactivity for a SARS-CoV-2 Beta-elicited antibody toward omicron sub-lineages.

Structure (London, England : 1993)·2026
Same author

Contemporary HIV-1 envelope pseudovirus panels for detecting and assessing B cell lineages with broadly neutralizing antibody potential.

bioRxiv : the preprint server for biology·2025
Same author

Transplacental transferred anti-SARS-CoV-2 neutralizing antibodies in unvaccinated pregnant women in Cameroon occurred during the COVID-19 pandemic, but not in the pre-pandemic period.

Frontiers in immunology·2025
Same author

VRC01 Selects Rare HIV Escape Mutations After Acquisition in Antibody-Mediated Prevention Trials.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Apr 16, 2026

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

4.4K

HIV broadly neutralizing antibody targets.

Constantinos Kurt Wibmer1, Penny L Moore, Lynn Morris

  • 1aCentre for HIV and STIs, National Institute for Communicable Diseases (NICD), National Health Laboratory Service (NHLS) bFaculty of Health Sciences, University of the Witwatersrand, Johannesburg cCentre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.

Current Opinion in HIV and AIDS
|March 12, 2015
PubMed
Summary

Recent advances in HIV-1 research reveal new antibody targets on the virus's envelope trimer. These findings, along with improved antibody isolation techniques, offer promising strategies for HIV-1 prevention and therapy.

More Related Videos

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
07:10

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

14.9K
Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

20.1K

Related Experiment Videos

Last Updated: Apr 16, 2026

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

4.4K
Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
07:10

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

14.9K
Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

20.1K

Area of Science:

  • Virology
  • Immunology
  • Structural Biology

Background:

  • HIV-1 envelope trimer structure is crucial for viral entry.
  • Broadly neutralizing antibodies (bNAbs) are key to controlling HIV-1 infection.
  • Understanding antibody targets informs vaccine and therapeutic development.

Purpose of the Study:

  • Update on neutralizing antibody targets based on recent HIV-1 envelope trimer structures.
  • Describe novel antibody isolation technologies.
  • Discuss implications for HIV-1 prevention and therapy.

Main Methods:

  • High-resolution structural analysis (crystal and cryo-EM) of HIV-1 trimers.
  • Advanced B-cell technologies for antibody isolation.
  • Characterization of antibody epitopes on the HIV-1 envelope.

Main Results:

  • New neutralization targets identified at the gp120-gp41 interface.
  • Importance of prefusion gp41 as an antibody target highlighted.
  • Glycan-dependent epitopes are significant for bNAbs.
  • Continuum of vulnerability across the HIV-1 envelope trimer revealed.

Conclusions:

  • Stabilized whole HIV-1 trimers show potential as immunogens.
  • Development of multi-epitope targeting antibodies is supported.
  • Broad and potent antibodies offer new avenues for HIV-1 prevention and treatment.